Terms: = Skin cancer AND ETV1, DKFZp781L0674, 2115, ENSG00000006468, ER81, MGC120533, MGC104699, MGC120534
11 results:
1. Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors.
Wong P; Wisneski AD; Tsai KK; Chang TT; Hirose K; Nakakura EK; Daud AI; Maker AV; Corvera CU
World J Surg Oncol; 2024 Mar; 22(1):77. PubMed ID: 38468341
[TBL] [Abstract] [Full Text] [Related]
2. Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol-3-kinase inhibitors: A systematic review and meta-analysis of randomized controlled trials.
Wang Y; Ma Z; An Z; Zhang Y; Feng X; Yu X
Cancer Med; 2023 Feb; 12(3):2227-2237. PubMed ID: 35986570
[TBL] [Abstract] [Full Text] [Related]
3. Disparities in quality of life, social distress and employment outcomes in Australian cancer survivors.
White VM; Lisy K; Ward A; Ristevski E; Clode M; Webber K; Emery J; Ijzerman MJ; Afshar N; Millar J; Gibbs P; Evans S; Jefford M
Support Care Cancer; 2022 Jun; 30(6):5299-5309. PubMed ID: 35279769
[TBL] [Abstract] [Full Text] [Related]
4. Dualism of FGF and TGF-β Signaling in Heterogeneous cancer-Associated Fibroblast Activation with etv1 as a Critical Determinant.
Bordignon P; Bottoni G; Xu X; Popescu AS; Truan Z; Guenova E; Kofler L; Jafari P; Ostano P; Röcken M; Neel V; Dotto GP
Cell Rep; 2019 Aug; 28(9):2358-2372.e6. PubMed ID: 31461652
[TBL] [Abstract] [Full Text] [Related]
5. Simultaneous integrated boost with helical arc radiotherapy of total skin (HEARTS) to treat cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia - dosimetry comparison of different regimens and clinical application.
Hsieh CH; Tien HJ; Yu YB; Wu YH; Shueng PW; Lu YF; Wang SY; Wang LY
Radiat Oncol; 2019 Jan; 14(1):17. PubMed ID: 30691490
[TBL] [Abstract] [Full Text] [Related]
6. COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors.
Xie Y; Cao Z; Wong EW; Guan Y; Ma W; Zhang JQ; Walczak EG; Murphy D; Ran L; Sirota I; Wang S; Shukla S; Gao D; Knott SR; Chang K; Leu J; Wongvipat J; Antonescu CR; Hannon G; Chi P; Chen Y
J Clin Invest; 2018 Apr; 128(4):1442-1457. PubMed ID: 29360641
[TBL] [Abstract] [Full Text] [Related]
7. Epigenetic and genetic dissections of UV-induced global gene dysregulation in skin cells through multi-omics analyses.
Shen Y; Stanislauskas M; Li G; Zheng D; Liu L
Sci Rep; 2017 Feb; 7():42646. PubMed ID: 28211524
[TBL] [Abstract] [Full Text] [Related]
8. miR-17 regulates melanoma cell motility by inhibiting the translation of etv1.
Cohen R; Greenberg E; Nemlich Y; Schachter J; Markel G
Oncotarget; 2015 Aug; 6(22):19006-16. PubMed ID: 26158900
[TBL] [Abstract] [Full Text] [Related]
9. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with etv1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract] [Full Text] [Related]
10. ERK/p90(RSK)/14-3-3 signalling has an impact on expression of PEA3 Ets transcription factors via the transcriptional repressor capicúa.
Dissanayake K; Toth R; Blakey J; Olsson O; Campbell DG; Prescott AR; MacKintosh C
Biochem J; 2011 Feb; 433(3):515-25. PubMed ID: 21087211
[TBL] [Abstract] [Full Text] [Related]
11. An oncogenic role for etv1 in melanoma.
Jané-Valbuena J; Widlund HR; Perner S; Johnson LA; Dibner AC; Lin WM; Baker AC; Nazarian RM; Vijayendran KG; Sellers WR; Hahn WC; Duncan LM; Rubin MA; Fisher DE; Garraway LA
Cancer Res; 2010 Mar; 70(5):2075-84. PubMed ID: 20160028
[TBL] [Abstract] [Full Text] [Related]
